RxAll Inc., a company co-founded by Lagos Business School (LBS) alumnus,
Adebayo Alonge of the Full-time MBA 11 class, has emerged grand winner of the
2019 Hello Tomorrow Challenge.
Alonge’s company, RxAll was picked out of
4,500 deeptech startups from 119 countries across the world that applied for
the 2019 edition of the Hello Tomorrow Global Challenge, a worldwide renowned
science and technology startup competition explicitly designed to address the
needs of deeptech entrepreneurs across several different industries and
technologies.
The Challenge gives scientists and deeptech
entrepreneurs around the globe a platform for their research and projects,
providing equity-free prize money as well as other funding opportunities,
global visibility and connections with key players in the deeptech innovation
network. 80 finalists were chosen from 12 categories
including Aeronautics, Data & AI, Digital Health, Energy, Food,
Agriculture & Environment, Global Health and others.
RxAll Inc. has built an Artificial
Intelligence (AI) platform that uses a proprietary molecular sensor device
known as RxScanner to carry out non-destructive drug authentication. The
RxScanner is a portable, easy-to-use nanoscanner that is used in testing drugs
for quality in real time thus preventing patients from using counterfeit
products.
Receiving the €100,000 award at the
Grand Finals of the Challenge in Paris, Alonge said, “It has been a long
journey for me, from 15 years before surviving death from a fake drug to
standing in front of you and letting you be in my dream and the dream of my co-founders
to make sure people across the world are safe from fake medicine.”
“My goal is to use science and the solution
we have today to make sure no one has to go through the trauma that I
experienced. Therefore, I invite everyone here today to join us in the vision
of using deeptech to achieve global social impact.”
Alonge, who is a pharmacist and marketing
development professional, also holds a business degree from Yale School of
Management. – LBS.edu.ng
No comments:
Post a Comment